Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
CollPlant Biotechnologies's 3-Year RORE % for the quarter that ended in Mar. 2026 was 11.95%.
The industry rank for CollPlant Biotechnologies's 3-Year RORE % or its related term are showing as below:
CLGN's 3-Year RORE % is ranked better than 75.48% of 1289
companies
in the Biotechnology industry
Industry Median: -11.44
vs CLGN: 11.95
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
CollPlant Biotechnologies 3-Year RORE % Related Terms
CollPlant Biotechnologies 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLGN vs CPMV, TCRT, DRMA: 3-Year RORE % Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
CollPlant Biotechnologies (CLGN) has a 3-Year RORE % of 11.95 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #316 out of 1289 companies in the Biotechnology industry, placing it in the top 24.5%.
Is CollPlant Biotechnologies' 3-Year RORE % too high?
CollPlant Biotechnologies' current 3-Year RORE % is 11.95. Based on the distribution chart, CollPlant Biotechnologies ranks #316 out of 1289 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' 3-Year RORE % compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #316 out of 1289 companies for 3-Year RORE %. This places CollPlant Biotechnologies in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current 3-Year RORE % is 11.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.37 — trading 27.4% above its estimated fair value. The current 3-Year RORE % is 11.95. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current 3-Year RORE % is 11.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.37 is trading 27.4% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
3-Year RORE %: 11.95
GF Value™: $0.29 vs. price of $0.37 (27.4% above fair value)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
